Cilostazol
Brand: Pletal (US/EU) / Cilacar (IN) / Cilodoc (IN) / Cilosta (BD)
Antiplatelet
PDE-III inhibitor (antiplatelet + vasodilator)
Pharmacokinetics
| Half-life | 12 hours |
| Tmax | 2.5 h |
| Bioavailability | 90 % (approx) |
| Protein Binding | 95 % |
| Volume of Distribution | 1.5 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Metabolized by CYP3A4 and CYP2C19; not for use in heart failure; improves walking distance in PAD. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Headache, palpitations, tachycardia, edema, diarrhea
Contraindications:
Heart failure of any severity (absolute), active bleeding
Precautions:
Monitor for tachyarrhythmias; avoid in HF due to increased mortality; dose adjust with strong CYP3A4 inhibitors